Episurf Medical (Nasdaq: EPIS B) today announces that it has entered into a distribution agreement with Joint Operations Ltd for several European countries. Initially targeted countries include Germany, UK, Ireland and Austria, with the possibility to add additional countries going forward. By the agreement, Episurf Medical will significantly expand the reach of its sales force in the selected markets, while also benefiting from Joint Operations' experience within joint reconstruction and small implants.  

"I am pleased with announcing our co-operation with Joint Operations which covers Europe's most important markets from day one, with the opportunity to add additional countries going forward. Joint Operations has excellent reach within their organisation and within their network, and they have significant experience from the joint reconstruction and small implant field. For Episurf, this means that we have one key partner for a big part of Europe, including a reduction in our general overhead and marketing expenses, which very well matches our overall strategy of optimising our organisation and working with strong distributors and distribution partners globally. We are very impressed with the company that Richard Forster and his team have built, and we look forward to the next steps together", says Pål Ryfors, CEO Episurf Medical.  

Joint Operations is a UK based distributor of products and solutions for joint preservation and extremities. The group has extensive experience within its targeted market segments, and the group has either direct or indirect representation in several markets in Europe, the Middle East, Africa and the US. In Germany, Joint Operations is active through its subsidiary 2med GmbH, which was acquired in 2020.   

"Our strategy is to interrupt the road toward arthroplasty and revision arthroplasty by managing arthritic progression at an earlier stage, and we believe that Episurf is a perfect partner for us, as their products fit extremely well into our strategy. We are very impressed with the clinical foundation that the company relies upon, and in our opinion, the Episealer® technology represents what many surgeons increasingly are asking for today", says Richard Forster, Managing Director and Co-founder, Joint Operations.  

The co-operation will come into force during the second quarter of 2025.